Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases

Autor: Sean P. Gavan, Ian N. Bruce, Katherine Payne, Ian Bruce, Mark Lunt, Niels Peek, Nophar Geifman, Sean Gavan, Gillian Armitt, Patrick Doherty, Jennifer Prattley, Narges Azadbakht, Angela Papazian, Helen Le Sueur, Carmen Farrelly, Clare Richardson, Zunnaira Shabbir, Lauren Hewitt, Neil McHugh, Caroline Gordon, John Reynolds, Stephen Young, David Jayne, Vern Farewell, Li Su, Matthew Pickering, Elizabeth Lightstone, Alyssa Gilmore, Marina Botto, Timothy Vyse, David Lester Morris, David D’Cruz, Edward Vital, Miriam Wittmann, Paul Emery, Michael Beresford, Christian Hedrich, Angela Midgley, Jenna Gritzfeld, Michael Ehrenstein, David Isenberg, Mariea Parvaz, Jane Dunnage, Jane Batchelor, Elaine Holland, Pauline Upsall, Hazem Youssef, Liza McCann, Rapti Mediwake, Anurag Bharadwaj, Ed Vital, Deepti Kapur, Prof Chee-Seng Yee, Bridget Griffiths, Abid Yusuf, Asad Zoma, Erin Vermaak, Francesco Carlucci, Richard Watts, Patrick Gordon, Shireen Shaffu, Jananath Wijeyekoon, Zoe McLaren, Yasmeen Ahmad, Mike Batley, Luke Gompels, T. Sheeran, Cee Yi Yong, Rachel Jeffery, Shahir Hamdulay, Fouz Rahmeh, Steven Young Min, Ben Rhodes, Denise De Lord, Peter Lanyon, Antoni Chan, Lee-Suan Teh, Jonathan Marks, David Hutchinson, Marian Regan, Richard Haigh, Richard Stratton, Ceril Rhys-Dillon, Mohamed Akil, Devesh Mewar, Sarah Skeoch, Nicola Erb, Edmond O’Riordan, Sarah Bartram, Mary Gayed, Bhaskar Dasgupta, Harsha Gunwardena, Dev Pyne, Arvind Kaul, Madhu Mahindrakar, Bhrigu Raj Sood, Nicola Gullick, Christopher Edwards, null Joanna C Robson, Jon King, Adrian Farrell, Sahena Haque, Sally Knights

Publikováno v: Gavan, SP, Bruce, IN, Payne, K & Consortium, MASTERPLANS 2022, ' Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases ', Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research . https://doi.org/10.1016/j.jval.2022.07.001

Objectives: This study aimed to demonstrate how to estimate the value of health gain after patients with a multisystem disease achieve a condition-specific composite response endpoint. Methods: Data from patients treated in routine practice with an e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a4de3893abbdacf5f5ac15ec1b2c61d
https://pubmed.ncbi.nlm.nih.gov/36008224

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

POS0608 SWITCHING OF TREATMENT FROM REFERENCE ETANERCEPT TO SANDOZ ETANERCEPT BIOSIMILAR IN PATIENTS WITH RHEUMATIC DISEASES: AN INTERIM ANALYSIS OF REAL-WORLD DATA FROM THE COMPACT STUDY

Autor: A. Askari, M. Schmalzing, T. Sheeran, J. C. Vazquez Perez-Coleman, David A. Walsh, F. Furlan, H. Kellner, C. Both, S. Hachaichi, J. De Toro Santos

Publikováno v: Annals of the Rheumatic Diseases. 80:540.1-540

Background:Sandoz etanercept (SDZ ETN) is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with SDZ ETN treatment in patients (pts) with rheumatoid arthritis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::216ab5a8e3361fb1f64199206ce9897d
https://doi.org/10.1136/annrheumdis-2021-eular.1490